

Binje Vick

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8117612/publications.pdf>

Version: 2024-02-01

22
papers

1,747
citations

623574

14
h-index

713332

21
g-index

23
all docs

23
docs citations

23
times ranked

3405
citing authors

#	ARTICLE	IF	CITATIONS
1	The target landscape of clinical kinase drugs. <i>Science</i> , 2017, 358, .	6.0	609
2	Small-molecule inhibition of METTL3 as a strategy against myeloid leukaemia. <i>Nature</i> , 2021, 593, 597-601.	13.7	531
3	Endogenous TCR promotes in vivo persistence of CD19-CAR-T cells compared to a CRISPR/Cas9-mediated TCR knockout CAR. <i>Blood</i> , 2020, 136, 1407-1418.	0.6	91
4	An Advanced Preclinical Mouse Model for Acute Myeloid Leukemia Using Patients' Cells of Various Genetic Subgroups and In Vivo Bioluminescence Imaging. <i>PLoS ONE</i> , 2015, 10, e0120925.	1.1	78
5	SRPK1 maintains acute myeloid leukemia through effects on isoform usage of epigenetic regulators including BRD4. <i>Nature Communications</i> , 2018, 9, 5378.	5.8	60
6	Targeting RSPO3-LGR4 Signaling for Leukemia Stem Cell Eradication in Acute Myeloid Leukemia. <i>Cancer Cell</i> , 2020, 38, 263-278.e6.	7.7	59
7	Loss of KDM6A confers drug resistance in acute myeloid leukemia. <i>Leukemia</i> , 2020, 34, 50-62.	3.3	56
8	Hepatic leukemia factor is a novel leukemic stem cell regulator in DNMT3A, NPM1, and FLT3-ITD triple-mutated AML. <i>Blood</i> , 2019, 134, 263-276.	0.6	41
9	RIG-I-based immunotherapy enhances survival in preclinical AML models and sensitizes AML cells to checkpoint blockade. <i>Leukemia</i> , 2020, 34, 1017-1026.	3.3	33
10	JMJD1C-mediated metabolic dysregulation contributes to HOXA9-dependent leukemogenesis. <i>Leukemia</i> , 2019, 33, 1400-1410.	3.3	31
11	Prime-seq, efficient and powerful bulk RNA sequencing. <i>Genome Biology</i> , 2022, 23, 88.	3.8	31
12	Anti-leukemic effects of the V-ATPase inhibitor Archazolid A. <i>Oncotarget</i> , 2015, 6, 43508-43528.	0.8	26
13	Loss-of-function mutations in the histone methyltransferase EZH2 promote chemotherapy resistance in AML. <i>Scientific Reports</i> , 2021, 11, 5838.	1.6	22
14	ZBTB7A prevents RUNX1-RUNX1T1-dependent clonal expansion of human hematopoietic stem and progenitor cells. <i>Oncogene</i> , 2020, 39, 3195-3205.	2.6	18
15	Plasticity in growth behavior of patients' acute myeloid leukemia stem cells growing in mice. <i>Haematologica</i> , 2020, 105, 2855-2860.	1.7	15
16	Azacitidine combined with the selective FLT3 kinase inhibitor crenolanib disrupts stromal protection and inhibits expansion of residual leukemia-initiating cells in FLT3-ITD AML with concurrent epigenetic mutations. <i>Oncotarget</i> , 2017, 8, 108738-108759.	0.8	14
17	Targeting the endoplasmic reticulum-mitochondria interface sensitizes leukemia cells to cytostatics. <i>Haematologica</i> , 2019, 104, 546-555.	1.7	10
18	In vivo inducible reverse genetics in patients' tumors to identify individual therapeutic targets. <i>Nature Communications</i> , 2021, 12, 5655.	5.8	10

#	ARTICLE	IF	CITATIONS
19	Frequent and reliable engraftment of certain adult primary acute lymphoblastic leukemias in mice. <i>Leukemia and Lymphoma</i> , 2019, 60, 848-851.	0.6	4
20	Genetic Profiling By Targeted, Deep Resequencing Confirms That a Murine Xenograft Model Of Acute Myeloid Leukemia (AML) Recapitulates The Mutational Landscape Of The Human Disease and Provides Evidence For Clonal Heterogeneity and Clonal Evolution. <i>Blood</i> , 2013, 122, 49-49.	0.6	2
21	Tyrosin Kinase Inhibition Restores the Membrane Localization of FLT3-ITD. <i>Blood</i> , 2015, 126, 1274-1274.	0.6	1
22	Adverse stem cell clones within a single patient's tumor predict clinical outcome in AML patients. <i>Journal of Hematology and Oncology</i> , 2022, 15, 25.	6.9	1